Cancer PainNCT03189277
A Hospital Based Survey on Lung Cancer Related-pain in Northern China
An observational study of Cancer Pain and Lung Cancer, run by Chinese Academy of Medical Sciences.
Trial summary
This cross-sectional study, utilizing two sets of questionaire designed for patients and physicians respectively, aims at the epidemiology, the clinical features, and the current status of evaluation and management of lung cancer related pain in 20 participating hospitals in Northern China. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cancer Pain, Lung Cancer
- How many people
- 2,000 participants
- Where
- No sites listed yet
- Study dates
- Jun 2017to Sep 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This is a cross-sectional study of clinical features (including prevalence, intensity and impact on life) of cancer-related pain in all lung cancer patients visiting the 20 participating hospitals in northern China on the designated day in July 2017. Meanwhile, all physicians receiving lung cancer patients in these hospitals are also enrolled to evaluate current management of lung cancer related pain in northern China. The patients will be identified in both outpatient clinics and inpatient wards of the involved hospitals. Informed consent will be obtained from participating patients and those who are not willing to provide pain information of interest and refuse to sign the ICF will be excluded.
Who may be able to join
- The patient questionaire
- All patients (outpatient and inpatient) diagnosed with lung cancer visiting the participating hospitals on the designated day of investigation
- Informed consent must be obtained from the participating patients
- The physician questionaire
- All physicians who receive lung cancer patients (outpatient and inpatient) in the participating hospitals on the designated day of investigation
Who cannot join
None listed.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Clinical Characteristics, Evaluation and Management of Lung Cancer Related-pain in Northern China: a Hospital-based Cross-sectional Study
This cross-sectional study, utilizing two sets of questionaire designed for patients and physicians respectively, aims at the epidemiology, the clinical features, and the current status of evaluation and management of lung cancer related pain in 20 participating hospitals in Northern China.
Read the detailed description
Lung malignancies have become the most common cause of mortality among patients with cancer in China. A significant proportion of lung cancer patients suffer from cancer related pain, however few studies have reported the prevalence and clinical features of such pain, especially in China.
This study is a cross-sectional survey in 20 hospitals in Northern China. We designed two separate series of questions to be answered by patients and cancer management professionals. In the patient questionaire, we collect information on the prevalence, location, intensity, impact on life of lung cancer related pain. Questions on how doctors evaluate and manage the pain are included in both the patients' and physicians' surveys. In the doctors' questionaire, we also assess current situation of cancer pain educational programs attended in medical schools and post graduation through related questions.
- Conditions
- Cancer Pain, Lung Cancer
- Medical subject headings
- Cancer Pain, Lung Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of cancer-related pain in lung cancer patients in 20 hospitals in northern China
the proportion of self-reported pain related to cancer affecting the enrolled lung cancer patients over the past 24 hours
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2017
- Study startJun 2017 (estimated)
- Primary completionSep 2017 (estimated)
- Study completionSep 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese Academy of Medical Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Chest Hospital, 307 Hospital of PLA, Peking Union Medical College Hospital, Beijing Chao Yang Hospital, Peking University Third Hospital, Peking University First Hospital, Beijing Shuyi Hospital, Daxing Hospital Beijing, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University General Hospital, Hebei Medical University Fourth Hospital, Henan Cancer Hospital, Shanxi Province Cancer Hospital, Inner Mongolia People's Hospital, The First Affiliated Hospital of Zhengzhou University, 309th Hospital of Chinese People's Liberation Army
- Responsible party
- Principal investigator, Shi Yuankai, Chinese Academy of Medical Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03189277
- Sponsor's protocol ID
- CH-PT-002
- Status last verified
- Jun 2017
- First submitted
- 14 Jun 2017
- Last updated
- 16 Jun 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Characteristics, Evaluation and Management of Lung Cancer Related-pain in Northern China: a Hospital-based Cross-sectional Study
- ClinicalTrials.gov ID
- NCT03189277
- Acronym / sponsor ID
- CH-PT-002
- Conditions
- Cancer Pain, Lung Cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Chinese Academy of Medical SciencesUniversity, hospital or other
- Collaborators
- Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Chest Hospital, 307 Hospital of PLA, Peking Union Medical College Hospital, Beijing Chao Yang Hospital, Peking University Third Hospital, Peking University First Hospital, Beijing Shuyi Hospital, Daxing Hospital Beijing, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University General Hospital, Hebei Medical University Fourth Hospital, Henan Cancer Hospital, Shanxi Province Cancer Hospital, Inner Mongolia People's Hospital, The First Affiliated Hospital of Zhengzhou University, 309th Hospital of Chinese People's Liberation Army
- Study start
- Jun 2017 (estimated)
- Primary completion
- Sep 2017 (estimated)
- Study completion
- Sep 2017 (estimated)
- First posted
- 16 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study, utilizing two sets of questionaire designed for patients and physicians respectively, aims at the epidemiology, the clinical features, and the current status of evaluation and management of lung cancer related pain in 20 participating hospitals in Northern China.
Detailed description
Lung malignancies have become the most common cause of mortality among patients with cancer in China. A significant proportion of lung cancer patients suffer from cancer related pain, however few studies have reported the prevalence and clinical features of such pain, especially in China.
This study is a cross-sectional survey in 20 hospitals in Northern China. We designed two separate series of questions to be answered by patients and cancer management professionals. In the patient questionaire, we collect information on the prevalence, location, intensity, impact on life of lung cancer related pain. Questions on how doctors evaluate and manage the pain are included in both the patients' and physicians' surveys. In the doctors' questionaire, we also assess current situation of cancer pain educational programs attended in medical schools and post graduation through related questions.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This is a cross-sectional study of clinical features (including prevalence, intensity and impact on life) of cancer-related pain in all lung cancer patients visiting the 20 participating hospitals in northern China on the designated day in July 2017. Meanwhile, all physicians receiving lung cancer patients in these hospitals are also enrolled to evaluate current management of lung cancer related pain in northern China. The patients will be identified in both outpatient clinics and inpatient wards of the involved hospitals. Informed consent will be obtained from participating patients and those who are not willing to provide pain information of interest and refuse to sign the ICF will be excluded.
Key inclusion criteria (5 listed)
- The patient questionaire
- The physician questionaire
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of cancer-related pain in lung cancer patients in 20 hospitals in northern China
Time frame: 24 hours
the proportion of self-reported pain related to cancer affecting the enrolled lung cancer patients over the past 24 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2017.
- Individual participant dataSharing planned: No
Related trials for Cancer Pain
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Not yet recruiting
Lung Cancer and Aging: Improving Well-being for Older Adults With Lung Cancer
Lung Cancer
Active, not recruitingPhase 3
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
Misuse, Opioid
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer Pain and Lung Cancer, run by Chinese Academy of Medical Sciences.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yuankai Shi, MD (86-10-87788293, syuankaipumc@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of cancer-related pain in lung cancer patients in 20 hospitals in northern China (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2017.